Virtus LifeSci Biotech Products ETF [BBP] Stock Forecast

Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.

These ETF areas won in the third quarter of 2022.

Biotech and cryptocurrency -- two ETF areas outperformed last week.

Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Virtus LifeSci Biotech Products ETF (BBP) rose 1.8%, the SPDR S&P Biotech ETF (XBI) increased 3.6%, and the ALPS Medical Breakthroughs ETF (SBIO) was up 3.9%.

Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday, the Virtus LifeSci Biotech Products ETF (BBP) rose 7.2%, the SPDR S&P Biotech ETF (XBI) increased 5.2%, and the ALPS Medical Breakthroughs ETF (SBIO) was up 5.1%.

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech Clinical Trials ETF (BBC) gained 15.5%, the Virtus LifeSci Biotech Products ETF (BBP) rose 12.8%, the SPDR S&P Biotech ETF (XBI) increased 11.3% and the ALPS [.

Biotech ETFs was the biggest gainer last week.